Companion diagnostic for combination lenalidomide and erythropoietin treatment
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorAlan F. List
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a companion diagnostic to predict efficacy of combination lenalidomide and erythropoietin treatment in patients with a erythropoietin (Epo)-refractory, Lower Risk (LR) Non-deletion 5q [Del(5q)] myelodysplasia syndrome (MDS). The method involves assaying erythroid precursors from a biological sample from the subject for a CD45 isoform profile, and treating the subject with a combination of lenalidomide and erythropoietin if the erythroid precursors have a predominance of large CD45RA and CD45RB isoforms compared to small CD45RO isoform.
Claims12
A method for treating a patient with a erythropoietin (Epo)-refractory, Lower Risk (LR) Non-deletion 5q [Del(5q)] myelodysplastic syndrome (MDS), comprising assaying CD71Hi erythroid precursors from a biological sample from a patient in need thereof for a CD45 isoform profile, and treating the patient with a combination of lenalidomide and erythropoietin if the erythroid precursors have a predominance of small CD45 RO isoform compared to large CD45 RA and CD45 RB isoforms.
The method of claim 2, wherein the erythropoietin comprises recombinant erythropoietin.
A method for predicting whether a patient with a erythropoietin (Epo)-refractory, Lower Risk (LR) Non-deletion 5q [Del(5q)] myelodysplastic syndrome (MDS) will respond to treatment with lenalidomide and erythropoietin, comprising assaying CD71Hi erythroid precursors from a biological sample from a patient in need thereof for a CD45 isoform profile, wherein a predominance of small CD45 RO isoform compared to large CD45 RA and CD45 RB isoforms is an indication that the patient will respond to treatment with lenalidomide and erythropoietin.
Dependencies are inferred from the claim text.